Jonathan Olefson Joins as General Counsel and Corporate Secretary
Robert Parks Joins as Chief Accounting Officer
RALEIGH, N.C., - November 14, 2018 - Syneos HealthTM (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), today announced the appointments of Jonathan Olefson as General Counsel and Corporate Secretary and Robert “Bobby” Parks as Chief Accounting Officer (CAO).
As General Counsel and Corporate Secretary, Olefson will lead Syneos Health’s global Legal, Compliance and Quality functions, bringing extensive expertise in data analytics, intellectual property and global markets to the organization. He will report directly to Syneos Health CEO Alistair Macdonald. As CAO, Parks will oversee shared services, SEC reporting, SOX compliance and accounting policies/research, reporting to Syneos Health CFO Jason Meggs.
“The addition of Jonathan and Bobby to the Syneos Health team underscores our ability to attract top talent, due in part to our compelling business model and promising growth opportunities,” said Alistair Macdonald, CEO of Syneos Health. “We are pleased to have Jonathan and Bobby step into these important roles as we continue to strengthen our leadership team and deliver on our mission to help customers bring life-changing treatments to patients.”
Prior to Syneos Health, Olefson served as the Senior Vice President, General Counsel and Secretary of Cotiviti Holdings, where he led the company’s successful transition to a publicly traded company. Before joining Cotiviti Holdings, he served as Vice President and General Counsel (Corporate, M&A and Intellectual Property) of Cognizant Technology Solutions, holding leadership positions including Chief Intellectual Property Counsel and lead attorney for Corporate Development and M&A. He holds a B.A. from Emory University and a J.D. from the George Washington University Law School.
Macdonald continued, “Jonathan has significant understanding of the consulting and healthcare industries, and we are fortunate to have someone with his expertise guide our go-forward efforts.”
Parks previously served as the Senior Vice President, Corporate Controller and Principal Accounting Officer of IQVIA, where he played an integral role in the Quintiles IPO in 2013 and the merger and integration with IMS Health. Prior to IQVIA, Parks served in leadership roles at both public and private companies, including CAO at TMX Finance, head of SEC reporting and SOX compliance at Allscripts and Controller at N.E.W. Customer Service. He holds a B.S. in accounting from the University of Maryland, College Park. He is a certified public accountant.
“We are confident that Bobby’s experience in post-acquisition environments will be invaluable as we continue to scale our accounting and compliance activities in-line with our expanding business,” added Syneos Health Chief Financial Officer, Jason Meggs.
About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 23,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.
Investor Relations Contact:
Senior Vice President, Investor Relations
+1 919 745 2745
Executive Director, External Communications
+1 202 210 5992
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: reliance on key personnel; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; the Company's ability to adequately price its contracts and not overrun cost estimates; any adverse effects from the Company's customer or therapeutic area concentration; the Company's ability to maintain or generate new business awards; the Company's ability to increase its market share, grow its business, and execute its growth strategies; the Company's backlog not being indicative of future revenues and its ability to realize the anticipated future revenue reflected in its backlog; risks associated with the integration of the Company's business with the business of inVentiv Health and its operation of the combined business following the closing of the Merger; the impact of adoption of the new accounting standard of recognizing revenue from customers; the impact of the Tax Act; the Company's ability to adequately price its contracts and not overrun cost estimates; fluctuations in the Company's financial results; and the other risk factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and other SEC filings, copies of which are available free of charge on the Company's website at investor.syneoshealth.com. Syneos Health assumes no obligation and does not intend to update these forward-looking statements, except as required by law.